All Updates

All Updates

icon
Filter
Partnerships
Absci partners with Memorial Sloan Kettering to develop AI-driven cancer therapeutics
AI Drug Discovery
Aug 12, 2024
This week:
Partnerships
Microsoft and BlackRock partner to launch USD 30 billion AI data center investment fund
Machine Learning Infrastructure
Today
Funding
Limitless Labs raises USD 3 million in pre-seed funding to develop prediction market
Web3 Ecosystem
Today
Product updates
Google Cloud launches Blockchain RPC service for Web3 developers
Web3 Ecosystem
Today
Product updates
Kore.ai launches GALE platform for enterprise GenAI adoption
Machine Learning Infrastructure
Today
Product updates
Kore.ai launches GALE platform for enterprise GenAI adoption
Generative AI Infrastructure
Today
Product updates
ProAmpac launches enhanced online pouch configurator MAKR by DASL for custom flexible packaging prototypes
Smart Packaging Tech
Yesterday
Funding
M&A
Majority stake in Bollegraaf Group acquired by Summa Equity for EUR 800 million
Waste Recovery & Management Tech
Yesterday
Partnerships
NASA awards Intuitive Machines contract for near-space network services
Space Travel and Exploration Tech
Yesterday
Partnerships
FinFit partners with Sunny Day Fund to offer emergency savings accounts
Financial Wellness Tools
Yesterday
Partnerships
KSP partners with Peak Technologies and Locus Robotics for warehouse automation
Logistics Tech
Yesterday
AI Drug Discovery

AI Drug Discovery

Aug 12, 2024

Absci partners with Memorial Sloan Kettering to develop AI-driven cancer therapeutics

Partnerships

  • AI-driven drug development company Absci has partnered with Memorial Sloan Kettering Cancer Center (MSK) to create up to six novel cancer therapeutics using GenAI.

  • The collaboration will combine Absci's AI and wet lab technologies with MSK's oncology expertise. MSK will identify cancer targets, while Absci will design antibodies using AI. This partnership aims to accelerate the discovery and development of new cancer treatments, with promising targets for preclinical development expected by the end of 2024.

  • This collaboration is Absci's first with a non-profit research institute, adding to its existing collaborations with major companies like AstraZeneca, Merck, and NVIDIA. The partnership reflects a broader trend of using AI for drug discovery and development, particularly in oncology.

Contact us

Gain access to all industry hubs, market maps, research tools, and more
Get a demo
arrow
menuarrow

By using this site, you agree to allow SPEEDA Edge and our partners to use cookies for analytics and personalization. Visit our privacy policy for more information about our data collection practices.